Baxter International Inc. (BAX) Stock Analysis
Momentum Cont setup
Healthcare · Medical Instruments & Supplies
Sell if holding. Engine safety override at $20.24: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 13%; Below-average business quality.
Baxter International manufactures essential healthcare products — IV solutions, infusion devices, parenteral nutrition, pharmaceuticals, smart beds, and patient monitoring — across three segments (Medical Products & Therapies, Healthcare Systems & Technologies, Pharmaceuticals),... Read more
Sell if holding. Engine safety override at $20.24: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 13%; Below-average business quality. Chart setup: Trend continuation, RSI 66, MACD bullish. Score 4.3/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 49d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Baxter International Inc.
About Baxter International Inc.
Baxter International provides hospitals, nursing homes, ambulatory surgery centers, and home patients with essential healthcare products manufactured in over 20 countries and sold in over 100 countries as of December 31, 2025. Following the divestiture of the BPS business for $3.96 billion in September 2023 and the Kidney Care business for $3.80 billion in January 2025, Baxter comprises three segments — Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals — employing approximately 37,500 people globally with roughly $9.48 billion of indebtedness outstanding.
Baxter's Medical Products & Therapies segment generates revenue from sterile IV solutions, infusion systems, parenteral nutrition, and surgical hemostat and sealant products. Healthcare Systems & Technologies sells smart bed systems, patient monitoring, respiratory health devices, and advanced surgical equipment — capabilities expanded through the 2021 Hillrom acquisition, which the company continues to integrate. The Pharmaceuticals segment covers specialty injectables, inhaled anesthetics, and drug compounding services. Customers include hospitals, GPOs, IDNs, and alternate-site providers; in the United States, distributors Cardinal Health and Medline warehouse and ship a significant portion of products. R&D expenditure totaled $518 million in 2025 compared to $590 million in 2024, with facilities in Belgium, India, Italy, Malta, and the United States. The company targets a net leverage ratio of approximately 3.0x by the end of 2026, supported by $3.81 billion in legacy debt repayment completed in 2025.
Show full overview
Baxter's manufacturing footprint spans more than 20 countries but concentrates certain raw materials sourced from single-source suppliers without contractual arrangements — a risk that became visible when Hurricane Helene-related clinical practice changes reset demand levels in the IV solutions business, as the 10-K acknowledges, negatively affecting premix product sales. The FDA, EMA, MHRA, Health Canada, and China's NMPA all subject manufacturing facilities to periodic inspections; warning letters or import restrictions at a facility lacking a qualified alternate site could disrupt production across one or more product categories, compounding existing supply chain exposure.
See also: Healthcare · Medical Instruments & Supplies
From Baxter International Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-06-11Recent Developments — Baxter International Inc.
Latest news
- NEWS FDA Issues Early Alert Regarding Pressure Breathing Device Issue from Baxter — benzinga Jun 11, 2026 negative
- NEWS Citigroup Downgrades Baxter International to Sell, Lowers Price Target to $17 — benzinga May 28, 2026 negative
- NEWS Barclays Maintains Overweight on Baxter International, Raises Price Target to $27 — benzinga May 4, 2026 positive
- NEWS Baxter Profit Plunges 35% As Tariffs, Costs Bite — benzinga May 1, 2026 negative
- NEWS Baxter International Affirms FY2026 Adj EPS Guidance of $1.85-$2.05 vs $1.91 Est; Affirms FY2026 Sales Guidance of $11.2 — benzinga Apr 30, 2026 neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomerGPOs, IDNs, and certain other distributors10-K Item 1A: 'Segments of our business are significantly dependent on major contracts with GPOs, IDNs, and certain other distributors and purchasers'
- HIGHSuppliersingle source suppliers10-K Item 1: 'certain of these materials are secured from single source suppliers or on a spot basis and not pursuant to a contractual arrangement'
- MEDIUMSupplierCardinal Health and Medline10-K Item 1: 'third parties, such as Cardinal Health, Inc. and Medline Inc., warehouse and ship a significant portion of our products through their distribution centers'
Material Events(8-K, last 90d)
- 2026-03-16Item 5.02MEDIUMCFO Joel Grade's service as EVP and CFO ceased effective March 16, 2026; he transitioned to a non-executive advisory role through April 30, 2026. Anita Zielinski appointed Interim CFO same date. Departure not due to disagreement with management.SEC filing →
- 2026-05-08Item 5.02LOWBaxter adopted new Executive Severance and Change in Control Plan effective May 4, 2026, superseding prior plan. Covers VP-and-above employees including Interim CFO Anita Zielinski. CEO Andrew Hider governed by separate offer letter terms.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -9.7%. Quality floor flags this regardless of sector context.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $20.24: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 13%; Below-average business quality. Chart setup: Trend continuation, RSI 66, MACD bullish. Prior stop was $18.89. Score 4.3/10, moderate confidence.
Take-profit target: $20.56 (+1.6% upside). Prior stop was $18.89. Stop-loss: $18.89.
Concentration risk — Supplier: single source suppliers; Target reached (-7.4% upside); Quality below floor (3.2 < 4.0).
Baxter International Inc. trades at a P/E of N/A (forward 10.1). TrendMatrix value score: 7.2/10. Verdict: Sell.
24 analysts cover BAX with a consensus score of 2.7/5. Average price target: $22.
What does Baxter International Inc. do?Baxter International manufactures essential healthcare products — IV solutions, infusion devices, parenteral nutrition,...
Baxter International manufactures essential healthcare products — IV solutions, infusion devices, parenteral nutrition, pharmaceuticals, smart beds, and patient monitoring — across three segments (Medical Products & Therapies, Healthcare Systems & Technologies, Pharmaceuticals), selling to hospitals and other healthcare facilities in over 100 countries. Following the divestitures of its BPS (September 2023) and Kidney Care (January 2025) businesses, the company employs approximately 37,500 people globally.